Hikma Pharmaceuticals (HIK) Competitors GBX 1,932 +2.00 (+0.10%) As of 08:34 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock HIK vs. HCM, INDV, AMYT, AGY, APH, ANCR, VLG, EAH, DNL, and STXShould you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry. Hikma Pharmaceuticals vs. Its Competitors HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Animalcare Group Venture Life Group ECO Animal Health Group Diurnal Group Shield Therapeutics Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Does the media refer more to HIK or HCM? In the previous week, Hikma Pharmaceuticals' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score. Company Overall Sentiment Hikma Pharmaceuticals Neutral HUTCHMED Neutral Which has more risk and volatility, HIK or HCM? Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Do analysts rate HIK or HCM? Hikma Pharmaceuticals currently has a consensus target price of GBX 2,560, indicating a potential upside of 32.51%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is HIK or HCM more profitable? Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets Hikma Pharmaceuticals9.45% 12.71% 9.40% HUTCHMED -6.87%-5.71%-5.90% Which has higher valuation & earnings, HIK or HCM? Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHikma Pharmaceuticals£3.74B1.43£353.21M£101.9118.96HUTCHMED£771.01M3.73-£52.98M-£3.92-67.64 Do institutionals and insiders believe in HIK or HCM? 42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryHikma Pharmaceuticals beats HUTCHMED on 11 of the 14 factors compared between the two stocks. Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIK vs. The Competition Export to ExcelMetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£5.36B£2.13B£5.52B£3.08BDividend Yield2.65%2.92%4.73%5.02%P/E Ratio18.964.2429.14176.49Price / Sales1.43679.35372.89315,127.59Price / Cash8.3410.3524.4827.97Price / Book1.8811.058.514.53Net Income£353.21M£21.15B£3.24B£5.90B7 Day Performance-2.23%-0.25%0.65%13.81%1 Month Performance-2.37%3.65%7.97%11.27%1 Year Performance4.09%3.95%30.78%74.69% Hikma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIKHikma Pharmaceuticals3.4129 of 5 starsGBX 1,932+0.1%GBX 2,560+32.5%+2.4%£5.36B£3.74B18.969,100HCMHUTCHMEDN/AGBX 277+5.3%N/A-9.2%£3.01B£771.01M-70.701,760Gap UpHigh Trading VolumeINDVIndivior2.9901 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+18.2%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 8.29-2.5%N/A+62.0%£407.46M£72.18M-7.99612Gap UpHigh Trading VolumeAPHAlliance Pharma2.0602 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 269+0.4%N/A+0.0%£184.43M£84.90M5.02220VLGVenture Life GroupN/AGBX 58.13+0.2%N/A+27.8%£74.07M£51.77M98.64165EAHECO Animal Health Group3.5369 of 5 starsGBX 80+3.2%GBX 150+87.5%-30.3%£54.21M£89.44M51.71234DNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133STXShield TherapeuticsN/AGBX 4.60-4.2%N/A+69.8%£45.40M£20.92M-1.1940,000 Related Companies and Tools Related Companies HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Animalcare Group Alternatives Venture Life Group Alternatives ECO Animal Health Group Alternatives Diurnal Group Alternatives Shield Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HIK) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HIK Stock Alerts